Objective: The aim of the study was the evaluation of risperidone effect on metabolite measures in the frontal lobe, temporal lobe and thalamus in schizophrenic patients on the basis of proton magnetic resonance spectroscopy (1H MRS). Methods: A group of 14 patients with the diagnosis of schizophrenia, according to DSM-IV, were examined in the study. The patients were examined twice, once after a period of at least 7 days without neuroleptics and for the second time at least 4 weeks after stable risperidone doses. Results: The significant differences in the metabolite levels before and after the treatment were observed only in thalamus: an increase in myoinositol (mI) and N-acetylaspartate (NAA) levels. Positive symptoms before the treatment correlated positively with NAA level in the frontal lobes and negatively in the temporal lobes. Negative symptoms before the treatment correlated positively with Glx (a common signal for GABA, glutamine and glutamate) level in the temporal lobes. Conclusion: Our results seem to confirm the influence of risperidone on the brain metabolism, specifically in the region of thalamus.
30 January 2008 in Alcohol, Clinical and Experimental Research
Zaburzenia funkcji poznawczych są integralną częścią obrazu klinicznego depresji, ale nie poświęca się im zasadniczej uwagi, głównie z powodu przekonania, że są one wtórne wobec innych, typowych objawów depresji. Uważa się, że dysfunkcje poznawcze stanowią jedną z przyczyn złego funkcjonowania chorych na depresję. Deficyty poznawcze są obecne już w pierwszym epizodzie depresji. Uważa się, że są one związane z nasileniem objawów depresji, hospitalizacją, wiekiem i wykształceniem chorych na depresję. Mogą się utrzymywać pomimo istotnej poprawy w zakresie innych objawów depresyjnych. Deficyty poznawcze w depresji dzielą się na „zimne” (niezwiązane z emocjami) i „gorące” (związanym z emocjami). Te deficyty kognitywne związane z poznaniem zimnym wydają się nie ustępować w czasie remisji, a przetrwałe deficyty tego typu wiążą się z gorszą reakcją na leki przeciwdepresyjne. Wortioksetyna to nowy lek przeciwdepresyjny o unikalnych mechanizmie działania: wpływa nie tylko na transport zwrotny serotoniny, ale wykazuje działanie agonistyczne wobec receptorów serotoninowych 5-HT 1A, będąc częściowym agonistą receptorów 5-HT 1B lub antagonistą receptorów 5-HT 1D , 5-HT 3 i 5-HT 7. W badaniach przedklinicznych, wortioksetyna znacząco normalizowała neurotransmisję serotoninergiczną, noradrenergiczną i dopaminergiczną, a dodatkowo przez efekt GABAergiczny i glutaminianergiczny. Działa przeciwdepresyjnie, jest skuteczna w różnych postaciach depresji: ciężkiej, z lękiem, u osób starszych; okazała się skuteczna u chorych, którzy nie odpowiadają wystarczająco na leczenie lekami z grupy SSR lub SNRI. Wpływakorzystnienafunkcjepoznawcze u chorychnadepresję.
1 April 2012 in Clinical Schizophrenia & Related Psychoses
Social cognition captures affect recognition, social cue perception, "theory of mind," empathy, and attributional style. The aim of our study was to assess social cognition in schizophrenia inpatients being treated with first-generation antipsychotic drugs (FGAs), n=28 (perphenazine and haloperidol, FGAs) or with second-generation antipsychotic drugs (SGAs), n=56 (olanzapine and clozapine, SGAs). Eighty-four patients completed the Facial Expression Recognition Test, the Voice Emotion Recognition Test, the Short Recognition Memory Test for Faces, and the Reading the Mind in the Eyes Test. Patients also completed the Visual Object and Space Perception Test (VOSP) as a control task, which would not engage social cognition. The patients were compared with fifty healthy controls matched for age and gender. There were no significant differences on social cognitive performance between the FGA- and SGA-treatment groups. Nor was olanzapine superior to clozapine, FGAs or both. However, patients treated with FGAs performed significantly worse on VOSP compared to both groups treated with SGAs, a 10% difference. We cannot conclude that SGAs were associated with better social cognition than FGAs. However, there were small but significant advantages for SGAs in non-social visual processing function, as evaluated with the VOSP.
Effectiveness of antipsychotics in treating emotional and cognitive deficits in schizophrenia still remains controversial. The aim of our study was to assess emotional and cognitive functioning in schizophrenic inpatients currently treated with typical antipsychotics (perphenazine, perazine, fluphenazine, and haloperidol) and in another group of schizophrenic inpatients currently on atypical antipsychotics (olanzapine, risperidone, amisulpride, and quetiapine). One hundred patients with DSM-IV schizophrenia or schizoaffective disorders (39 treated using typical antipsychotics and 61 treated with atypical antipsychotics) under naturalistic treatment conditions, and 50 healthy controls were given the following: Test of Everyday Attention, Facial Emotion Recognition Test, Facial Memory Recognition Test, and “Reading the mind in the eyes” Test. Patients with a diagnosis of schizophrenia revealed the following deficits: facial emotion perception, empathy/theory of mind, visual selective attention/speed, attentional switching, and auditory-verbal working memory. Our results show a significant difference between schizophrenic and healthy controls in all tasks, with schizophrenic patients performing worse than controls. Interestingly, our patients on atypical neuroleptics performed similarly compared to schizophrenic patients treated with conventional neuroleptics on all tasks provided. There were some significant relationships between emotional and cognitive deficits and clinical variables. Our findings remain consistent with other recent studies in which atypical antipsychotics did not show a clear advantage over typical antipsychotics on both emotional and cognitive functioning.